THC applied to the skin can enter the bloodstream, but whether it does—and how much gets through—depends heavily on the product. Conventional cannabis creams and balms often produce little or no detectable systemic THC under studied conditions. Products specifically engineered for transdermal delivery can behave differently. Calling every skin-applied cannabis product “topical” hides a distinction that matters for intoxication, medication interactions, and drug testing.
The evidence therefore supports a qualified answer rather than an absolute yes or no. Skin absorption, measurable blood concentrations, feeling high, and testing positive are separate outcomes. A product may deliver cannabinoids into skin without producing substantial blood levels, and measurable exposure does not automatically mean noticeable intoxication. Understanding these differences makes it easier to evaluate labels and recognize what a manufacturer would need to demonstrate before promising that its product stays entirely outside your circulation.
Topical and Transdermal THC Are Not Interchangeable
In everyday language, “topical” describes something placed on the body’s surface. In drug delivery, topical treatment generally aims for an effect at or near the application site. A transdermal formulation is designed to move an active ingredient across the skin into systemic circulation. Both can look like creams or gels, while patches may be designed for different delivery goals. The product’s appearance alone cannot establish where its cannabinoids end up.
This distinction concerns intended delivery, not an impenetrable boundary between categories. Some products marketed for local use may still produce systemic absorption, while a product advertised as transdermal may lack convincing human data. Terms such as “deep penetrating,” “nano,” or “advanced delivery” are descriptions or marketing claims, not measurements. The useful question is whether the finished formulation has been tested in people, with blood sampling that shows the amount absorbed and the timing of exposure.
Why THC Does Not Easily Pass Through Skin
The outermost skin layer, the stratum corneum, is an effective barrier to many substances. THC dissolves readily in fats but poorly in water. That helps explain why it can associate with lipid-rich skin structures while having difficulty continuing through other tissue layers. Simply adding THC to an oily balm does not guarantee efficient transport into the small blood vessels beneath the surface. Product formulation matters as much as the presence of the cannabinoid.
Laboratory research illustrates this complexity. Audra Stinchcomb and colleagues’ 2004 study in the Journal of Pharmacy and Pharmacology examined the passage of delta-8 THC, CBD, and cannabinol through human skin in diffusion experiments. These were laboratory measurements, not demonstrations of intoxication in people, and delta-8 THC is not identical to the delta-9 THC usually meant by “THC.” Later formulation studies likewise distinguish cannabinoid retention within skin from movement across it. These are different endpoints, and neither should be casually substituted for a measured human blood concentration.
What Research on Conventional Creams Found
A frequently cited 2017 paper by C. Hess, M. Krämer, and B. Madea in Forensic Science International examined whether topical cannabis products could explain positive cannabinoid findings in a driver’s blood. Researchers conducted an application experiment involving two THC-containing preparations over three days. Under those experimental conditions, they did not detect THC or its metabolites in volunteers’ blood or urine. The findings supported their conclusion that those particular products could not explain the driver’s results.
The paper’s broad-sounding title has sometimes encouraged an overly broad interpretation. Its results do not demonstrate that every THC cream, patch, or future delivery system is incapable of systemic absorption. The formulations tested, their cannabinoid concentrations, the application procedure, and the analytical methods define what the experiment can establish. “Not detected” also means below a method’s detection capability in the samples collected; it is not proof that absolutely no molecules crossed the skin. The study is reassuring about the tested preparations, but it cannot provide a universal guarantee.
Human Evidence That Transdermal THC Can Reach Blood
Gyula Varadi and colleagues investigated a specially engineered delivery system in a study published online in 2022 and appearing in the 2023 volume of Advances in Therapy. Eighteen healthy adults received a skin-applied formulation containing 100 milligrams each of THC and CBD. Blood sampling over 12 hours demonstrated systemic exposure. Mean peak THC concentration was approximately 0.35 nanograms per milliliter, with substantial variation between participants. No participant reported feeling high.
This was a small, open-label, single-arm investigation of one formulation, so it does not establish the behavior or safety of every transdermal product. It nevertheless provides direct human evidence against the claim that skin-applied THC can never reach circulation. The amount applied also should not be confused with the amount absorbed: placing 100 milligrams on skin is not equivalent to swallowing that dose. The study establishes a delivery possibility, not a recommended dose, a reliable conversion to edibles, or proof of pain relief.
What a Larger Topical CBD Study Adds
In 2024, C. Austin Zamarripa and colleagues published a study in the Journal of Analytical Toxicology involving 46 healthy adults. Participants received one of five commercial hemp-derived topical products or placebo. Active preparations included a cream, lotion, patch, balm, and gel, with repeated application during the study. Although these were predominantly CBD products with low THC content, the experiment helps clarify why the behavior of one topical cannot be assumed to represent all others.
Three active products produced measurable transdermal CBD absorption. THC and its metabolites remained below detection limits in blood, and no urine samples met the cannabis-positive criteria used in the study. However, nine participants had oral-fluid THC concentrations at or above a threshold relevant to workplace testing. These findings must be interpreted together: they did not show detectable bloodstream THC, but neither did they support a blanket promise of negative results in every sample type. They also cannot establish the behavior of high-THC formulations.
Can a THC Cream Make You Feel High?
A conventional product with very limited systemic absorption is less likely to cause THC intoxication than a product delivering substantial THC into circulation. However, the word “cream” does not prove that systemic exposure is negligible. The delivery system, concentration, application conditions, and individual response all matter. Conversely, detecting a small quantity in blood does not establish that the person felt high or experienced meaningful impairment. Absorption and effects need to be measured separately.
A cooling sensation, warmth, or perceived relief at the application site is not evidence of THC reaching the brain. Other ingredients, rubbing the area, and expectations can contribute to what someone feels. If a product causes dizziness, altered perception, unusual drowsiness, or difficulty concentrating, stop using it and avoid driving or hazardous tasks. Seek medical advice if symptoms persist or are concerning. Do not keep applying more because a label promises that intoxication is impossible, particularly when the product is promoted as transdermal.
What Changes How Much THC Is Absorbed?
The full formulation influences drug release and passage through skin. In a 2020 experimental study published in Pharmaceutics, researchers compared CBD in different solvent systems and semisolid preparations, demonstrating the importance of the vehicle. Although CBD findings cannot supply a precise THC absorption rate, they show why equal cannabinoid quantities in different products need not produce equal delivery. Concentration, the amount applied, treated surface area, and duration of contact are all relevant to evaluating exposure.
Skin condition also limits how confidently findings can be generalized. A 2002 study in the International Journal of Pharmaceutics compared delta-9 THC passage through intact human skin and skin with its outer barrier removed. Such laboratory work underscores why results obtained with intact skin should not be assumed to apply to damaged tissue. Avoid applying products to wounds or irritated areas unless specifically directed by a clinician. Do not improvise with heating pads, tight coverings, added solvents, or other methods intended to increase penetration; the resulting exposure has not been established for your product.
Can Topical THC Cause a Positive Drug Test?
A negative blood result, a negative urine result, and a negative oral-fluid result answer different questions. Tests may look for THC itself or metabolites, and their sensitivity and reporting thresholds differ. Urine cannabinoid testing commonly targets a THC metabolite rather than measuring current intoxication. A product’s ability to avoid a noticeable high therefore cannot establish that it will avoid detection. Likewise, a positive test does not by itself identify the route of exposure.
The available research does not justify claiming that every ordinary balm will trigger a drug test, but it also does not justify guarantees that all topicals are undetectable. Transdermal THC introduces a clear reason for caution because systemic delivery is its purpose. People for whom a positive result would have serious consequences should not treat “topical,” “hemp,” or “nonintoxicating” as assurance. There is no well-validated universal waiting period after topical THC use that guarantees a negative test across products, application patterns, and testing methods.
Labels and Laboratory Reports Need Careful Reading
Product contents are another source of uncertainty. Tory Spindle and colleagues’ 2022 study in JAMA Network Open evaluated 105 topical CBD products purchased online and in stores. THC was detected in 37 products, or 35%, and CBD labeling was frequently inaccurate. This was a product-content investigation, not an absorption trial. Finding THC in a jar does not show how much enters blood, but it does demonstrate why a CBD label alone cannot establish that a preparation contains no THC.
A recent, batch-matched certificate of analysis can help clarify cannabinoid content. Look for the THC result, the units used, and whether the number refers to a gram, application, or entire container. “Not detected” should be interpreted alongside the laboratory’s detection or quantification limits. Even an accurate certificate does not show how the product behaves after application: chemical-content testing and human absorption testing are different forms of evidence. Ask manufacturers for product-specific data when they make confident promises about bloodstream exposure or drug testing.
What This Means for Safe, Informed Use
Follow the intended route and application instructions, and keep skin products away from the mouth, eyes, children, and pets. Mucosal exposure or accidental swallowing is a different situation from applying a preparation to intact skin. Local irritation is possible even without substantial absorption. People taking medicines should discuss transdermal THC or CBD with a pharmacist, because potential interactions depend on systemic exposure and the particular drugs involved. The FDA advises avoiding THC and CBD during pregnancy and breastfeeding; a topical label does not establish safety in those circumstances.
Finally, absorption is not the same as effectiveness. Demonstrating that THC reaches blood does not prove that a product treats arthritis, nerve pain, or another condition. Limited blood exposure does not, by itself, prove useful local treatment either. The clearest answer is that ordinary topicals often show limited systemic THC exposure, while specially formulated transdermal products can deliver THC into circulation. Assess the actual preparation, the quality of its evidence, and your reason for using it rather than relying on the assumption that everything applied to skin stays there.
